This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Palmer, C. P. Articles by Aydar, E. Search for Related Content PubMed PubMed Citation Articles by Palmer, C. P. Articles by Aydar, E.

Sigma-1 Receptors Bind Cholesterol and Remodel Lipid Rafts in Breast Cancer Cell Lines

Division of Cell and Molecular Biology, Faculty of Natural Sciences, Imperial College, London, United Kingdom

Requests for reprints: Ebru Aydar, Division of Cell and Molecular Biology, Faculty of Natural Sciences, Imperial College, Exhibition Road, South Kensington, London SW7 2AZ, United Kingdom. Phone: 44-207-5945440; Fax: 44-207-584-2056; E-mail: e.aydar{at}ic.ac.uk.

Lipid rafts are membrane platforms that spatially organize molecules for specific signaling pathways that regulate various cellular functions. Cholesterol is critical for liquid-ordered raft formation by serving as a spacer between the hydrocarbon chains of sphingolipids, and alterations in the cholesterol contents of the plasma membrane causes disruption of rafts. The role that receptors play in cancer is not clear, although it is frequently up-regulated in human cancer cells and tissues and receptors inhibit proliferation in carcinoma and melanoma cell lines, induce apoptosis in colon and mammary carcinoma cell lines, and reduce cellular adhesion in mammary carcinoma cell lines. In this study, we provide molecular and functional evidence for the involvement of the enigmatic 1 receptors in lipid raft modeling by 1 receptor–mediated cholesterol alteration of lipid rafts in breast cancer cell lines. Cholesterol binds to cholesterol recognition domains in the COOH terminus of the 1 receptor. This binding is blocked by receptor drugs because the cholesterol-binding domains form part of the receptor drug-binding site, mutations of which abolish cholesterol binding. Furthermore, we outline a hypothetical functional model to explain the myriad of biological processes, including cancer, in which these mysterious receptors are involved. The findings of this study provide a biological basis for the potential therapeutic applications of lipid raft cholesterol regulation in cancer therapy using receptor drugs. [Cancer Res 2007;67(23):11166–75]

This article has been cited by other articles:

				A. Pal, U. B. Chu, S. Ramachandran, D. Grawoig, L.-W. Guo, A. R. Hajipour, and A. E. Ruoho Juxtaposition of the Steroid Binding Domain-like I and II Regions Constitutes a Ligand Binding Site in the {sigma}-1 Receptor J. Biol. Chem., July 11, 2008; 283(28): 19646 - 19656. [Abstract] [Full Text] [PDF]